stockrow
Monday 9 November 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
- Revenue
- −43.9%
- EPS
- +11.3%
- Free cash flow
- −7.05%
Quarter to September 2026, against a year earlier
4.89
0.34
+7.47%
Follow TRDA
Alert me
Entrada Therapeutics, Inc. (TRDA) P/E ratio
Entrada Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 23.5× (June 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 8.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 23.5×
Ten-year median
0.0×
Current reading's percentile
75
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)